ArticleEuropean heart journal open2024
Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate risk.
Article in European heart journal open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Substantial Change Between Repeated Lipoprotein(a) Measurements Is Associated with Residual Cardiovascular Risk in a Real-World Multicenter Cohort.Journal of clinical medicine · 2026Article
- Role of Lipoprotein(a) in Aortic Valve Calcification: Inflammatory and Oxidative Mechanisms Involved.International journal of molecular sciences · 2026Review
- Lipoprotein(a) and Women's Cardiovascular Health: A Review.JACC. Advances · 2026Article
- Impact of lipoprotein(a) on the durability of aortic bioprosthetic valves.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Evaluating the Whole Patient: Lessons from the Pre-CKM Era Toward Integrated Cardio-Kidney-Liver-Metabolic Care.Life (Basel, Switzerland) · 2026Article
- Intra-Individual Variability of Lipoprotein(a) After Acute Coronary Syndrome: A Long-Term Cohort Study.Journal of clinical medicine · 2026Article
- Intraindividual Lp(a)-Variability in a Real-World Setting.JACC. Advances · 2026Article
- Impact of Lipoprotein(a) on Residual Cardiovascular Risk After an Acute Coronary Syndrome.Journal of clinical medicine · 2026Review
- The biology of lipoprotein(a): From genetics to molecular mechanisms.European journal of clinical investigation · 2026Review
- Lipoprotein(a) in clinical practice: Risk stratification and therapeutic strategies.European journal of clinical investigation · 2026Review
- Identifying barriers to lipoprotein(a) testing in secondary cardiovascular prevention and co-designing implementation strategies: an Italian behavior change wheel-informed study.Frontiers in cardiovascular medicine · 2026Article
- Is a Single Lipoprotein(a) Measurement Once in a Lifetime Sufficient? The Results from the STAR-Lp(a) Study.Medical sciences (Basel, Switzerland) · 2025Article
- Lp(a) in Argentina: Regional data reinforce a global risk factor.Atherosclerosis · 2025Article
- Lipoprotein(a) prevalence trends in Portuguese children and adolescents: a real-world perspective.Clinical and experimental pediatrics · 2025Article
- Characterizing Lipoprotein(a) in Children With New-Onset Diabetes and Implications for Cardiovascular Risk Assessment.Journal of the Endocrine Society · 2025Article
- Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications.Diabetes, obesity & metabolism · 2025Review
- Predictors of lipoprotein(a) variability in clinical practice and their impact on cardiovascular risk.Lipids in health and disease · 2025Observational
- Lipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution.Lipids in health and disease · 2025Article
- Lipoprotein(a) and Effects of Diet: Time for Reassessment.Nutrients · 2025Review
- Lipoprotein(a) as an early marker of cardiovascular events in high-risk subjects: insights from the Moli-sani cohort study.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Aims: Lipoprotein(a) [Lp(a)] levels are predominantly genetically determined and repeat measurements are generally considered unlikely to be clinically useful. However, the temporal variation of Lp(a) is not well characterized. Our aim was to determine the intra-individual variability of Lp(a) and whether a repeated measure reclassified Lp(a)-specific cardiovascular risk using the European Atherosclerosis Society (EAS) consensus statement risk categories. Methods and results: This retrospective cohort study analysed initial and repeated serum Lp(a) levels measured using the same methodology from 609 individuals in the Nashville Biosciences database, a de-identified electronic medical records database. Baseline and follow-up paired values were significantly different ( Conclusion: Temporal-related changes in Lp(a) variability were present in many individuals. A repeat Lp(a) measure may allow more precise Lp(a)-specific cardiovascular risk prediction for individuals whose initial value is in the EAS-defined intermediate 'grey-zone' category. Lp(a) variability should be included in calculating the expected effect sizes in future clinical research studies targeting Lp(a).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.